SMC accepts dronedarone

Dronedarone will be available in NHS Scotland after it was accepted by the Scottish Medicines Consortium (SMC).

The SMC approved the drug for use in patients in whom conventional first-line, anti-arrhythmic medicines are ineffective, contraindicated or not tolerated.

It said although a study showed that dronedarone is less effective than amiodarone in reducing AF recurrence, it is better tolerated.

The study found a lower rate of thyroid, liver, lung, nerve, skin, eye and digestive side effects for the dronedarone treatment group than the amiodarone group.

However, more digestive events, such as diarrhoea, were reported for the dronedarone group compared with the amiodarone group.

The institute said: ‘SMC accepted dronedarone for use in NHS Scotland because it was considered to be value for money and has the potential for an improved safety profile over its comparators.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in